Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Medical Oncology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sonpavde, G.
Right arrow Articles by Rosenberg, J. E.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Novel agents for advanced bladder cancer

Guru Sonpavde

Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, D1230, 44 Binney Street, Boston, MA 02115, USA, jonathan_rosenberg{at}dfci.harvard.edu

Aymen A. Elfiky

Genitourinary Oncology Program, Texas Oncology, Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd, Webster, TX 77598, USA

Jonathan E. Rosenberg

Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, D1230, 44 Binney Street, Boston, MA 02115, USA

Conventional front-line platinum-based combination chemotherapy yields high response rates but suboptimal long-term outcomes for advanced transitional cell carcinoma. Salvage therapy is an unmet need with disappointing outcomes. The emergence of novel biologic agents offers the promise of improved outcomes. Neoadjuvant therapy preceding cystectomy for muscle-invasive bladder cancer provides an important paradigm and an interesting approach in developing novel agents. Patients who are not candidates for cisplatin require special attention. A multidisciplinary approach and collaboration among laboratory scientists, oncologists, urologists and radiation oncologists is necessary to make therapeutic advances. Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed.

Key Words: transitional cell carcinoma • chemotherapy • biologic agents

Therapeutic Advances in Medical Oncology, Vol. 1, No. 1, 37-50 (2009)
DOI: 10.1177/1758834009337776
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?